脂肪来源再生细胞联合脂肪移植治疗乳腺癌相关淋巴水肿:淋巴显像评估与1年随访
该首次人体试点研究纳入10例乳腺癌相关淋巴水肿患者,将脂肪来源再生细胞(ADRCs)直接注射至腋窝区域并联合瘢痕松解脂肪移植。随访1年,患者报告结局显著改善,5例减少保守治疗使用,但臂体积和淋巴显像定量均无显著改善,仅见脂肪抽吸相关轻微一过性不良事件。
要点
- ADRCs联合脂肪移植可显著改善患者报告结局,但臂体积无显著变化。
- 淋巴显像定量评估显示患侧淋巴回流无改善。
- 治疗耐受良好,仅见脂肪抽吸相关轻微一过性不良事件。
核心结论
- 单次ADRCs注射基于患者报告结局指标改善了淋巴水肿,随访期间无严重不良事件。
- 淋巴显像评估显示ADRCs治疗后无改善, excess arm volume无变化。
- 该试点试验结果需在随机临床试验中确认。
研究设计与样本
- 首次人体试点研究,纳入10例乳腺癌相关淋巴水肿患者。
- ADRCs直接注射至腋窝区域,联合瘢痕松解脂肪移植手术。
- 主要终点为臂体积变化,次要终点包括患者报告结局、淋巴流变化和安全性,随访1年。
主要发现
- 随访期间臂体积无显著变化。
- 患者报告结局随时间显著改善。
- 5例患者减少了保守治疗的使用。
- 定量淋巴显像在淋巴水肿患侧手臂无改善。
- ADRCs耐受良好,仅见脂肪抽吸相关轻微一过性不良事件。
临床怎么用
- ADRCs联合脂肪移植可能作为改善乳腺癌相关淋巴水肿患者报告结局的辅助手段。
- 治疗前应向患者说明臂体积和淋巴回流可能无显著改善。
- 需关注脂肪抽吸相关轻微一过性不良事件。
局限性
- 试点研究样本量小(10例),无对照组。
- 结果需随机临床试验确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast cancer-related lymphedema (BCRL) is a feared late complication. Treatment options are lacking at present. Recent studies have suggested that mesenchymal stromal cells can alleviate lymphedema. Herein, we report the results from the first human pilot study with adipose-derived regenerative cells (ADRCs) for treating BCRL with 1 year of follow-up. MATERIAL AND METHODS: We included 10 patients with BCRL. ADRCs were injected directly into the axillary region together with a scar-releasing fat grafting procedure. Primary endpoint was change in arm volume. Secondary endpoints were change in patient-reported outcomes, changes in lymph flow, and safety. RESULTS: During follow-up, no significant change in volume was noted. Patient-reported outcomes improved significantly with time. Five patients reduced their use of conservative management. Quantitative lymphoscintigraphy did not improve on the lymphedema-affected arms. ADRCs were well tolerated, and only minor transient adverse events related to liposuction were noted. CONCLUSIONS: In this pilot study, a single injection of ADRCs improved lymphedema based on patient-reported outcome measures, and there were no serious adverse events during the follow-up period. Lymphoscintigraphic evaluation showed no improvement after ADRC treatment. There was no change in excess arm volume. Results of this trial need to be confirmed in randomized clinical trials.
引用
- Toyserkani NM, Jensen CH, Tabatabaeifar S, et al. Adipose-derived regenerative cells and fat grafting for treating breast cancer-related lymphedema: Lymphoscintigraphic evaluation with 1 year of follow-up. J Plast Reconstr Aesthet Surg. 2018. PMID: 30293963. doi:10.1016/j.bjps.2018.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。